RxDoctor Payments Data

Evva Allen, APRN

Family · Lexington, KYNPI 1457930430

Payments from drug & device makers

$7,280in general payments, 2019–2025

Across 327 payments — averaging $22.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Amgen$1K
  • Johnson & Johnson$875
  • UCB, Inc.$795
  • AbbVie$692
  • Boehringer Ingelheim$510
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$6,84794%
  • Education$4336%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,280 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$52,996
Medicare patients
379
Services billed
2,919

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab75$571,763
RinvoqUpadacitinib44$282,022
Enbrel SureclickEtanercept26$189,317
Xeljanz XrTofacitinib Citrate20$113,124
Orencia ClickjectAbatacept17$105,146
OtezlaApremilast21$96,082
Actemra ActpenTocilizumab15$60,856
Hydroxychloroquine Sulfate442$12,662
Leflunomide166$10,869
MethotrexateMethotrexate Sodium491$9,308
Celecoxib117$5,604
Duloxetine Hcl211$3,978
Mycophenolate Mofetil29$3,172
Febuxostat25$2,879
Pregabalin95$2,768

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$692$282,02244 claims
AmgenOtezla$1,099$96,08221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.

Other family in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →